ReviewMolecular biology reports2026
Sugar transporter SLC45 gene family members: roles in malignant tumors and research progress.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The SLC45 family emerges as a proton-coupled sugar transport system that complements the classical SGLT (SLC5) and GLUT (SLC2) transporters in mammals. This review synthesizes recent advances on four family members (SLC45A1–A4), covering their structural features (12-pass transmembrane topology with a pH-sensing cytoplasmic loop), genomic organization across chromosomes 1p36.1, 5p13.3, 1q32.1, and 8q24.3, and diverse physiological roles in brain glucose homeostasis, melanogenesis, lipid metabolism, and cancer metabolic reprogramming. We highlight disease associations, including SLC45A1 mutations causing epileptic encephalopathy, SLC45A2 variants linked to oculocutaneous albinism and melanoma risk, SLC45A3 fusions driving prostate cancer, and SLC45A4 overexpression in ovarian/pancreatic cancers. Recent literature reveals tissue-specific regulatory mechanisms (e.g., androgen signaling for SLC45A3, TP53-MYC axis for SLC45A4) and therapeutic potential spanning ketogenic diets, gene therapy, peptide vaccines, and siRNA nanoliposomes. We conclude by identifying critical knowledge gaps—such as the lack of mammalian structures and undefined substrate spectra—that must be addressed to translate SLC45 biology into precision medicine.
Indexed as
Identifiers
41524821What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.